Women in HIV trials: improving adherence and outcomes

Affiliations

¹ Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. Electronic address: susan-cohn@northwestern.edu.

Comment

Susan E Cohn. Lancet HIV. 2017 Dec.

. 2017 Dec;4(12):e530-e531.

doi: 10.1016/S2352-3018(17)30107-8. Epub 2017 Jul 17.

¹ Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. Electronic address: susan-cohn@northwestern.edu.

No abstract available

Comment on

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Orrell C, Hagins DP, Belonosova E, Porteiro N, Walmsley S, Falcó V, Man CY, Aylott A, Buchanan AM, Wynne B, Vavro C, Aboud M, Smith KY; ARIA study team. Orrell C, et al. Lancet HIV. 2017 Dec;4(12):e536-e546. doi: 10.1016/S2352-3018(17)30095-4. Epub 2017 Jul 17. Lancet HIV. 2017. PMID: 28729158 Clinical Trial.